Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (111-120 of 274) with videos related to

Pageof 28
Sort By:
Blood Advances|July 17, 2025
The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell LeukemiaAsis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2015
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman DiseaseCorey Casper, Shalini Chaturvedi, Nikhil Munshi, et al.
Blood Advances|January 29, 2020
Long-term outcomes after autologous stem cell transplantation for multiple myelomaKatherine K Nishimura, Bart Barlogie, Frits van Rhee, et al.
Blood Advances|February 12, 2025
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myelomaBhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, et al.
Haematologica|September 4, 2025
The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site studyMichael A Bauer, Phillip Farmer, Joseph L Su, et al.
American Journal of Hematology|April 21, 2018
Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman diseaseSheila K Pierson, Aaron J Stonestrom, Dustin Shilling, et al.
Haematologica|June 13, 2012
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsSaad Z Usmani, Christoph Heuck, Alan Mitchell, et al.
Immunotherapy|February 19, 2016
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Sharmilan Thanendrarajan, Faith E Davies, Gareth J Morgan, et al.
Nature Communications|November 26, 2022
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman diseaseSheila K Pierson, Laura Katz, Reece Williams, et al.
Vaccine|January 11, 2014
Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vectorRamesh B Batchu, Oksana V Gruzdyn, Amberly M Moreno-Bost, et al.
Pageof 28

Showing results (111-120 of 274) with videos related to

Sort By:
Pageof 28
Blood Advances|July 17, 2025
The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell LeukemiaAsis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2015
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman DiseaseCorey Casper, Shalini Chaturvedi, Nikhil Munshi, et al.
Blood Advances|January 29, 2020
Long-term outcomes after autologous stem cell transplantation for multiple myelomaKatherine K Nishimura, Bart Barlogie, Frits van Rhee, et al.
Blood Advances|February 12, 2025
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myelomaBhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, et al.
Haematologica|September 4, 2025
The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site studyMichael A Bauer, Phillip Farmer, Joseph L Su, et al.
American Journal of Hematology|April 21, 2018
Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman diseaseSheila K Pierson, Aaron J Stonestrom, Dustin Shilling, et al.
Haematologica|June 13, 2012
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsSaad Z Usmani, Christoph Heuck, Alan Mitchell, et al.
Immunotherapy|February 19, 2016
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Sharmilan Thanendrarajan, Faith E Davies, Gareth J Morgan, et al.
Nature Communications|November 26, 2022
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman diseaseSheila K Pierson, Laura Katz, Reece Williams, et al.
Vaccine|January 11, 2014
Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vectorRamesh B Batchu, Oksana V Gruzdyn, Amberly M Moreno-Bost, et al.
Pageof 28